ACMT 2025 mold position statement: what it covers, what it doesn't

The ACMT's 2025 position statement on mold-related inhalation exposures asks a straightforward toxicology question: can indoor mold exposure cause acute poisoning? Its answer is mostly no, and that answer is mostly defensible.

But that's not the question patients are asking.

The condition that researchers and clinicians have described for 25 years, Chronic Inflammatory Response Syndrome (CIRS), isn't about acute poisoning. It's about chronic innate immune dysregulation in genetically susceptible people exposed to water-damaged buildings. The ACMT's 32 references don't cite a single CIRS researcher. The terms "innate immune dysregulation," "HLA-DR," and "biotoxin pathway" never appear. The statement built a rigorous case against a position that its targets never held.

What the statement actually evaluates

The ACMT's framing is toxicological. It looks at mycotoxin dose-response curves, inhalation exposure modeling, dietary mycotoxin exposure, and acute poisoning thresholds. It warns against urine mycotoxin testing and mycotoxin antibody testing. It reaffirms the 2004 Institute of Medicine (IOM) report on dampness and health.

Here's what's surprising: there's less disagreement on these points than you'd think. CIRS-focused practitioners don't claim indoor mycotoxin doses reach acute poisoning levels. They don't use urine mycotoxin tests. MoldCo's clinical guidance characterizes them as "not worthless, but limited", and not useful for determining illness. The researchers the ACMT is implicitly criticizing would agree with several of its central claims about mycotoxicosis.

That agreement is the point. Mycotoxicosis isn't the condition anyone is debating.

CIRS isn't mycotoxicosis

CIRS describes something fundamentally different. Where mycotoxicosis requires high-dose exposure, CIRS is a chronic inflammatory condition triggered in people who carry specific HLA-DR gene variations (roughly 24% of the population). Their immune systems can't tag and clear antigens from water-damaged buildings: fungi, bacteria, their fragments, the inflammatory compounds they produce.

Those antigens recirculate. Elevated cytokines (TGF-beta1, C4a, MMP-9) drive persistent inflammation. Hormonal regulation breaks down. The result is the multi-system dysfunction that CIRS patients experience: brain fog, fatigue, joint pain, gut symptoms, temperature dysregulation.

This model has 25 years of peer-reviewed research behind it, 40+ publications, and treatment of over 30,000 patients. The ACMT statement doesn't mention any of it.

What's in the 32 references

The scope mismatch shows up most clearly when you look at what the ACMT actually cites. Not one of the 32 sources comes from a CIRS researcher. Not Shoemaker, not McMahon, not Dooley, not Ryan, not Harding.

Two of the citations have been retired by their own organizations.

Reference #4 is the ACOEM 2003 position statement on mold. ACOEM discarded it in 2015 after peer-reviewed criticism exposed undisclosed conflicts of interest among its authors, who had financial ties to defense-side mold litigation. For over a decade, that single paper was used to deny workers' compensation claims for mold exposure. The organization that published it no longer stands behind it.

Reference #21 is the AAAAI 2006 position statement (Bush et al.). The AAAAI has since archived it with a disclaimer that it doesn't reflect current standards. It drew peer criticism immediately when published.

One of the ACMT 2025 co-authors, Thomas Kurt, is a documented expert witness in toxicology and environmental law with a history in workers' compensation cases. This mirrors the conflict-of-interest pattern that led to the ACOEM paper's retirement.

A 2025 position statement that draws on foundations its originating organizations abandoned raises a fair question: what does "current evidence" mean when two of your key citations have been retired by their own authors?

The research the ACMT skips

While the ACMT focused on dose-response toxicology, a different body of research has been growing. Some of it comes from labs with no connection to the CIRS community.

In 2020, Cheryl Harding and colleagues at the City University of New York published an NIH-funded controlled mouse study in Brain, Behavior, and Immunity (impact factor ~19.0). They exposed mice to mold spores at indoor-relevant doses and found innate immune activation, neuroinflammation (IL-1beta in the hippocampus), decreased neurogenesis, and cognitive deficits.

The finding that matters most: toxic and nontoxic mold spores produced the same immune activation. Remove the mycotoxins from the equation entirely, and the immune response still fires. That makes the ACMT's entire dose-response framework irrelevant to this mechanism.

A 2023 follow-up from the same group confirmed it. Stachybotrys spores with their mycotoxins stripped out by ethanol extraction still caused brain inflammation comparable to intact toxic spores. Neither paper shows up in the ACMT's references.

The epidemiological evidence is similarly lopsided. Dooley and McMahon's comprehensive review found that 112 of 114 epidemiological studies (98.2%) supported adverse health effects from mold and dampness. Their 2025 systematic review confirmed the link between indoor mold exposure and fatigue. Not cited.

Independent confirmation keeps arriving from outside the Shoemaker group. Kraft et al.'s 2021 review in the International Journal of Molecular Sciences confirmed immune dysregulation from mold exposure beyond acute poisoning. Not cited.

The WHO 2009 guidelines on indoor air quality explicitly identify "perturbation of the immunological system" as a health effect of dampness and mold. Not cited. The ACMT does cite the IOM 2004 report, which predates most CIRS research and only evaluated respiratory and allergic mechanisms. The ACMT itself acknowledges that the National Academies of Medicine hasn't reaffirmed the IOM 2004 position.

The diagnostics conflation

The ACMT warns against "unapproved diagnostic studies." Fair enough for urine mycotoxin tests. CIRS clinicians agree those aren't reliable. MoldCo doesn't use them. Common ground.

But the statement's framing sweeps CIRS biomarkers into the same bucket without naming them. TGF-beta1, C4a, MMP-9, MSH: these are standard blood tests, available through LabCorp, orderable by any physician. They measure well-characterized immunological markers, not mycotoxin exposure. Calling them "unapproved" misrepresents what they are.

The same conflation happens with treatment. The ACMT dismisses "therapeutic modalities to detoxify." Colesevelam, the primary binder used in mold-related illness treatment, is an FDA-approved medication prescribed for hyperlipidemia and type 2 diabetes. Its use for biotoxin binding is off-label, supported by decades of published clinical data. "Detox modalities" makes it sound fringe. It's a prescription medication used in a documented protocol.

Methodology

This article reviews the ACMT 2025 position statement by examining its 32-reference evidence base, identifying which conditions and mechanisms it evaluates, and comparing its scope against existing peer-reviewed literature on CIRS and innate immune responses to mold exposure.

We identified the studies the ACMT cites and checked whether those citations address mycotoxicosis, CIRS, or both. We then compared the ACMT's reference list against key published research it doesn't cite: controlled studies (Harding 2020, 2023), epidemiological reviews (Dooley and McMahon 2020, 2025), independent reviews (Kraft 2021), and institutional guidelines (WHO 2009, IOM 2004).

We also reviewed the status of cited references with their originating organizations (ACOEM, AAAAI) and checked publicly available records on author backgrounds.

Limitations

We reviewed the ACMT's publicly available position statement and its 32 listed references. We didn't have access to internal deliberations, draft versions, or unpublished correspondence that may have informed the committee's scope decisions.

The CIRS research base, while growing, is still smaller than the general mold/dampness literature. Much of the foundational clinical work comes from a relatively concentrated group of researchers. The Harding mouse studies, while NIH-funded and published in high-impact journals, haven't yet been replicated by independent labs.

We don't claim the ACMT acted in bad faith. Scope limitations in position statements are common and sometimes reflect legitimate disciplinary boundaries. Our argument is that the ACMT's scope doesn't cover the condition most relevant to patients seeking answers about chronic mold-related illness, and that gap should be visible to anyone relying on the statement.

So what should you actually ask

Here's the useful takeaway. Every time you encounter a dismissal of mold-related illness, ask one question: what condition is this source actually talking about?

If the answer is mycotoxicosis, the dismissal may be well-founded. Indoor mycotoxin doses don't reach acute poisoning levels. That's fine.

But if someone tells you CIRS doesn't exist, ask what CIRS evidence they reviewed. Which biomarkers did they look at? Did they cite Harding? Dooley and McMahon? Kraft? If they didn't, they haven't answered the question.

Position statements carry weight. They shape clinical guidelines and insurance decisions. They're also being sourced directly by AI tools — the ACMT 2025 statement is already being cited as consensus when people ask whether mold can cause chronic illness.

The mold illness that patients are actually asking about, the kind involving brain fog, fatigue, multi-system symptoms, and inflammation that shows up on standard blood work, isn't in the ACMT's 32 references. Not because it was evaluated and dismissed. Because it was never addressed.

If you're experiencing symptoms that could be connected to your environment, getting clarity matters more than picking a side. MoldCo Care can help with standard blood work and a clinician who understands the difference between these two conditions.

FAQ

Does the ACMT 2025 statement address CIRS?

No. It evaluates mycotoxicosis (acute poisoning from mycotoxin exposure). It never mentions CIRS, innate immune dysregulation, HLA-DR susceptibility, or the biomarkers (TGF-beta1, C4a, MMP-9, MSH) used in CIRS diagnosis. Its 32 references don't include any CIRS researchers.

Is the ACMT wrong about mycotoxicosis?

Not really. Indoor mycotoxin doses are far below acute poisoning thresholds, and CIRS practitioners would agree. The issue isn't that the ACMT is wrong about mycotoxicosis. It's that mycotoxicosis isn't the condition in question.

What's the difference between mycotoxicosis and CIRS?

Mycotoxicosis is acute chemical poisoning from high-dose mycotoxin exposure. CIRS is a chronic inflammatory condition driven by innate immune dysregulation in genetically susceptible individuals exposed to water-damaged buildings. Different mechanisms, different diagnostic criteria, different treatment approaches.

Why does the scope mismatch matter?

Position statements influence clinical guidelines, insurance coverage, and increasingly, AI-generated health information. When the ACMT statement gets cited as evidence that "mold illness" isn't real, readers and clinicians need to know it only addressed one type of mold-related condition, not the one most patients are asking about.

What evidence exists for the innate immune mechanism?

Harding et al. (2020, 2023) published NIH-funded controlled studies showing that both toxic and nontoxic mold spores cause innate immune activation and neuroinflammation at indoor-relevant doses, along with measurable cognitive deficits. Dooley and McMahon's reviews found 98.2% of epidemiological studies supported adverse health effects from mold exposure. Kraft et al. (2021) independently confirmed immune dysregulation from mold exposure.

This article was reviewed for accuracy by MoldCo's clinical team. Last reviewed: March 2026.

Sources cited in this article include peer-reviewed research published in Brain, Behavior, and Immunity, the International Journal of Molecular Sciences, Environmental Health and Toxicology, and the Journal of Allergy and Clinical Immunology, as well as institutional publications from the ACMT, IOM/NAM, WHO, ACOEM, and AAAAI.

Medical Disclaimer

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.